AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review
Section 1 - About the Company
AstraZeneca Plc - Key Facts
AstraZeneca Plc - Key Employees
AstraZeneca Plc - Key Employee Biographies
AstraZeneca Plc - Major Products and Services
AstraZeneca Plc - History
AstraZeneca Plc - Company Statement
AstraZeneca Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
AstraZeneca Plc - Business Description
Other Break-up: Alliance Revenue
Performance
Other Break-up: Collaboration Revenue
Overview
Performance
Other Break-up: Product Sales
Overview
Performance
Geographical Segment: Australia
Performance
Geographical Segment: Canada
Performance
Geographical Segment: China
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Others
Performance
Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: UK
Performance
Geographical Segment: US
Performance
R&D Overview
AstraZeneca Plc - Corporate Strategy
AstraZeneca Plc - SWOT Analysis
SWOT Analysis - Overview
AstraZeneca Plc - Strengths
AstraZeneca Plc - Weaknesses
AstraZeneca Plc - Opportunities
AstraZeneca Plc - Threats
AstraZeneca Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
AstraZeneca Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 12, 2024: AstraZeneca Invests $3.5 billion in R&D and Manufacturing in the United States
Nov 07, 2024: AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024
Oct 14, 2024: ENHERTU gains conditional approval in China to treat NSCLC
Oct 10, 2024: Alexion, AstraZeneca Rare Disease data at the 2024 AANEM Annual Meeting and MGFA Scientific Session further demonstrate advancement in gMG care
Sep 16, 2024: New Collaboration to Introduce Liquid Biopsy Testing for Lung Cancer
Sep 14, 2024: SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
Sep 03, 2024: AstraZeneca Advances Ambition to Improve Standards of Care in Multiple Cancer Types at WCLC and ESMO 2024
Aug 08, 2024: Conduit acquires three first-in-class assets from AstraZeneca